Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: CapTem chemotherapy regimen is a standard treatment for NETs but limited scientific data on its efficacy and tolerability are available
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Smiroldo V, Carnaghi C, Lania A, Bonifacio C, Pepe G,
Keywords: CapTem, metastatic neuroendocrine tumors,
Introduction: NETs are extremely heterogeneous in nature. Despite recent advances, few biomarkers are available to consistently predict prognosis and optimize treatment selection.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Chan D, Yao J, Carnaghi C, Buzzoni R, Herbst F,
Keywords: Neuroendocrine tumors, neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, everolimus, RADIANT-3, RADIANT-4, systemic inflammation, prognosis,
Introduction: Hyperglycemia and hypercholesterolemia are class effects of mTOR inhibitors such as everolimus (EVE).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F,
Keywords: adverse events, everolimus, RADIANT-3, RADIANT-4, landmark analysis, mTOR inhibitors, targeted therapy, neuroendocrine tumors,
Introduction: A 58-year-old woman was referred to our hospital for hepatic lesions and thickening of the walls of the stomach detected by abdominal CT scan. An upper GI endoscopy showed a lesion of the body of the stomach and the histopathologic exam documented a well differentiated NET. 68Ga-DOTATOC PET showed pathologic uptake in the stomach and in the liver (3 lesions). Circulating chromogranin A and gastrin were 596 ng/ml and 2283 pg/ml respectively
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Smiroldo V
Authors: Smiroldo V, Carnaghi C, Tresoldi A, Lania A, Bonifacio C,
Keywords: gastric, NET, complete remission, gastrin,
Introduction: In the RADIANT-4 study, everolimus (EVE) reduced the risk of disease progression or death by 52% vs placebo (PBO; P<0.00001) in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET of lung/GI tract.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Buzzoni R
Authors: Buzzoni R, Carnaghi C, Pommier R, Fazio N, Singh S,
Keywords: everolimus, SSA, nonfunctional NET,